Published in Cardiovasc Res on May 16, 2008
High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol (2013) 2.12
Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr (2010) 1.87
NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol (2011) 1.69
Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis (2011) 1.58
Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest (2012) 1.57
PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice. Arterioscler Thromb Vasc Biol (2013) 1.52
MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res (2009) 1.49
The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz) (2009) 1.45
CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest (2011) 1.39
Low ambient oxygen prevents atherosclerosis. J Mol Med (Berl) (2016) 1.38
CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol (2010) 1.37
NF-κB in Aging and Disease. Aging Dis (2011) 1.28
Pathogen-mediated inflammatory atherosclerosis is mediated in part via Toll-like receptor 2-induced inflammatory responses. J Innate Immun (2010) 1.21
Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev (2010) 1.18
Inactivation of the tumour suppressor, PTEN, in smooth muscle promotes a pro-inflammatory phenotype and enhances neointima formation. Cardiovasc Res (2010) 1.14
ATP-binding membrane cassette transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport. Mol Med (2010) 1.10
Il-19 reduces VSMC activation by regulation of mRNA regulatory factor HuR and reduction of mRNA stability. J Mol Cell Cardiol (2010) 1.08
Arsenic exacerbates atherosclerotic lesion formation and inflammation in ApoE-/- mice. Toxicol Appl Pharmacol (2009) 1.08
Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One (2012) 1.05
Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front Physiol (2012) 1.04
Increased aortic atherosclerotic plaque development in female apolipoprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production. J Physiol Pharmacol (2010) 1.03
Obesity and airway responsiveness: role of TNFR2. Pulm Pharmacol Ther (2012) 1.03
The expression of cytokines in the aqueous humor and serum during endotoxin-induced uveitis in C3H/HeN mice. Mol Vis (2010) 1.02
Adiponectin abates diabetes-induced endothelial dysfunction by suppressing oxidative stress, adhesion molecules, and inflammation in type 2 diabetic mice. Am J Physiol Heart Circ Physiol (2012) 1.02
Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory response. J Biol Chem (2011) 1.02
Macrophage autophagy in atherosclerosis. Mediators Inflamm (2013) 1.00
Genome-wide approaches reveal functional interleukin-4-inducible STAT6 binding to the vascular cell adhesion molecule 1 promoter. Mol Cell Biol (2011) 1.00
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev (2015) 1.00
MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases. J Exp Med (2014) 0.98
αMβ₂ integrin activation prevents alternative activation of human and murine macrophages and impedes foam cell formation. Circ Res (2011) 0.98
OxLDL-induced IL-1 beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation. Inflamm Res (2014) 0.98
Self-eating in the plaque: what macrophage autophagy reveals about atherosclerosis. Trends Endocrinol Metab (2014) 0.98
A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS One (2013) 0.96
The IL-33-ST2L pathway is associated with coronary artery disease in a Chinese Han population. Am J Hum Genet (2013) 0.96
High-fat diet induces lung remodeling in ApoE-deficient mice: an association with an increase in circulatory and lung inflammatory factors. Lab Invest (2009) 0.96
Cell-cell interactions mediate the response of vascular smooth muscle cells to substrate stiffness. Biophys J (2011) 0.95
Association of influenza virus infection and inflammatory cytokines with acute myocardial infarction. Inflamm Res (2012) 0.94
Interaction of adipocyte fatty acid-binding protein (AFABP) and JAK2: AFABP/aP2 as a regulator of JAK2 signaling. J Biol Chem (2009) 0.94
Macrophage Migration and Its Regulation by CSF-1. Int J Cell Biol (2012) 0.93
Association between blood pressure and DNA methylation of retrotransposons and pro-inflammatory genes. Int J Epidemiol (2013) 0.92
Opium addiction increases interleukin 1 receptor antagonist (IL-1Ra) in the coronary artery disease patients. PLoS One (2012) 0.91
Current status and challenges of cytokine pharmacology. Br J Pharmacol (2009) 0.91
Macrophage differentiation and function in atherosclerosis: opportunities for therapeutic intervention? J Innate Immun (2012) 0.90
Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury. J Am Heart Assoc (2012) 0.89
Alternatively activated macrophages determine repair of the infarcted adult murine heart. J Clin Invest (2016) 0.89
Familial mediterranean Fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. Open Cardiovasc Med J (2010) 0.87
Atherogenesis and iron: from epidemiology to cellular level. Front Pharmacol (2014) 0.87
The role of the vascular dendritic cell network in atherosclerosis. Am J Physiol Cell Physiol (2013) 0.87
Ubiquitin carboxyl terminal hydrolase L1 negatively regulates TNFalpha-mediated vascular smooth muscle cell proliferation via suppressing ERK activation. Biochem Biophys Res Commun (2009) 0.87
A change in inflammatory footprint precedes plaque instability: a systematic evaluation of cellular aspects of the adaptive immune response in human atherosclerosis. J Am Heart Assoc (2015) 0.86
Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis. J Biol Chem (2010) 0.86
The immune protective effect of the Mediterranean diet against chronic low-grade inflammatory diseases. Endocr Metab Immune Disord Drug Targets (2014) 0.86
Plasmacytoid dendritic cells in atherosclerosis. Front Physiol (2012) 0.86
Systemic levels of G-CSF and interleukin-6 determine the angiogenic potential of bone marrow resident monocytes. J Leukoc Biol (2010) 0.86
Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor-A and CD36. Cell Stress Chaperones (2013) 0.86
The future of EPAC-targeted therapies: agonism versus antagonism. Trends Pharmacol Sci (2015) 0.86
Attenuation of experimental atherosclerosis by interleukin-19. Arterioscler Thromb Vasc Biol (2013) 0.86
Cynical hostility and stimulated Th1 and Th2 cytokine production. Brain Behav Immun (2009) 0.85
Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions. Int J Nanomedicine (2011) 0.85
Metformin Down-regulates TNF-α Secretion via Suppression of Scavenger Receptors in Macrophages. Immune Netw (2013) 0.85
Circulating TNFalpha levels in older men and women do not show independent prospective relations with MI or stroke. Atherosclerosis (2008) 0.85
Pathways involved in interleukin-1β-mediated murine cardiomyocyte apoptosis. Tex Heart Inst J (2015) 0.85
Lymphocyte migration into atherosclerotic plaque. Arterioscler Thromb Vasc Biol (2014) 0.85
Fetal programming of the neuroendocrine-immune system and metabolic disease. J Pregnancy (2012) 0.84
Toll-like receptor 4 mediates inflammatory cytokine secretion in smooth muscle cells induced by oxidized low-density lipoprotein. PLoS One (2014) 0.84
Dietary epicatechin promotes survival of obese diabetic mice and Drosophila melanogaster. J Nutr (2011) 0.84
Absence of p55 TNF receptor reduces atherosclerosis, but has no major effect on angiotensin II induced aneurysms in LDL receptor deficient mice. PLoS One (2009) 0.84
Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression. Mol Cancer (2015) 0.83
A dietary mixture containing fish oil, resveratrol, lycopene, catechins, and vitamins E and C reduces atherosclerosis in transgenic mice. J Nutr (2011) 0.83
Insulin promotes macrophage foam cell formation: potential implications in diabetes-related atherosclerosis. Lab Invest (2012) 0.83
Atherosclerosis and the role of immune cells. World J Clin Cases (2015) 0.83
Mesenchymal Stem Cells Stabilize Atherosclerotic Vulnerable Plaque by Anti-Inflammatory Properties. PLoS One (2015) 0.83
Mast cell deficiency attenuates progression of atherosclerosis and hepatic steatosis in apolipoprotein E-null mice. Am J Physiol Heart Circ Physiol (2012) 0.83
Impact of obesity on IL-12 family gene expression in insulin responsive tissues. Biochim Biophys Acta (2012) 0.82
Homocysteine induces inflammatory transcriptional signaling in monocytes. Front Biosci (Landmark Ed) (2013) 0.82
Role of Macrophage Migration Inhibitory Factor in Obesity, Insulin Resistance, Type 2 Diabetes, and Associated Hepatic Co-Morbidities: A Comprehensive Review of Human and Rodent Studies. Front Immunol (2015) 0.82
Clinical significance of macrophage phenotypes in cardiovascular disease. Clin Transl Med (2014) 0.82
Oil palm phenolics attenuate changes caused by an atherogenic diet in mice. Eur J Nutr (2012) 0.82
A pro-inflammatory role of deubiquitinating enzyme cylindromatosis (CYLD) in vascular smooth muscle cells. Biochem Biophys Res Commun (2012) 0.82
IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis. J Immunol (2015) 0.82
Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study. AIDS Res Hum Retroviruses (2013) 0.81
Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids. J Lipid Res (2011) 0.81
Wild blueberries (Vaccinium myrtillus) alleviate inflammation and hypertension associated with developing obesity in mice fed with a high-fat diet. PLoS One (2014) 0.81
Deficiency of glycine N-methyltransferase aggravates atherosclerosis in apolipoprotein E-null mice. Mol Med (2012) 0.80
T lymphocyte autoreactivity in inflammatory mechanisms regulating atherosclerosis. ScientificWorldJournal (2012) 0.80
Environmental endocrine disruption of energy metabolism and cardiovascular risk. Curr Diab Rep (2014) 0.80
Maternal diet supplemented with methyl-donors protects against atherosclerosis in F1 ApoE(-/-) mice. PLoS One (2013) 0.80
Rapid and Efficient Production of Coronary Artery Ligation and Myocardial Infarction in Mice Using Surgical Clips. PLoS One (2015) 0.79
A Unique Combination of Nutritionally Active Ingredients Can Prevent Several Key Processes Associated with Atherosclerosis In Vitro. PLoS One (2016) 0.79
Inflammation imaging of atherosclerosis in Apo-E-deficient mice using a (99m)Tc-labeled dual-domain cytokine ligand. Nucl Med Biol (2014) 0.79
Expression and function of anti-inflammatory interleukins: the other side of the vascular response to injury. Curr Vasc Pharmacol (2009) 0.79
IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice. PLoS One (2015) 0.79
Magnetic resonance imaging of bone marrow cell-mediated interleukin-10 gene therapy of atherosclerosis. PLoS One (2011) 0.79
Association between Interleukin-1 gene single nucleotide polymorphisms and ischemic stroke classified by TOAST criteria in the Han population of northern China. Biomed Res Int (2013) 0.79
Red Blood Cell Dysfunction Induced by High-Fat Diet: Potential Implications for Obesity-Related Atherosclerosis. Circulation (2015) 0.79
Association between the -794 (CATT)5-8 MIF gene polymorphism and susceptibility to acute coronary syndrome in a western Mexican population. J Immunol Res (2014) 0.78
Atherosclerosis in juvenile idiopathic arthritis. Mediators Inflamm (2012) 0.78
Epigenetic regulation of NKG2D ligands is involved in exacerbated atherosclerosis development in Sirt6 heterozygous mice. Sci Rep (2016) 0.78
Gentiana scabra Reduces SR-A Expression and Oxidized-LDL Uptake in Human Macrophages. Acta Cardiol Sin (2016) 0.78
Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 15.65
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
The biology of interleukin-6. Blood (1989) 6.65
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 5.28
IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest (1998) 4.77
Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A (1995) 4.31
IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest (1997) 4.18
Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature (2000) 3.81
Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res (2002) 3.69
Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol (2005) 3.67
Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol (2007) 3.36
Protective role of interleukin-10 in atherosclerosis. Circ Res (1999) 3.28
Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (2003) 3.18
Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature (1990) 3.11
Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med (1998) 2.89
Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res (2002) 2.85
Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol (1999) 2.73
IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest (2004) 2.56
Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res (2003) 2.44
Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol (2004) 2.41
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today (1997) 2.37
Hemopoietic cell growth factors and their receptors. Annu Rev Biochem (1989) 2.28
The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol (2003) 2.20
Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol (1999) 2.17
The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med (2000) 2.17
T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol (2006) 2.12
Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect (2002) 2.10
Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med (2003) 1.95
Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation (2004) 1.82
Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol (2007) 1.80
Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol (2000) 1.80
The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (1999) 1.77
Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res (2002) 1.77
Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. J Clin Invest (1998) 1.76
IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2006) 1.73
Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res (2001) 1.70
Inhibition of progression and stabilization of plaques by postnatal interferon-gamma function blocking in ApoE-knockout mice. Circ Res (2007) 1.70
Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol (2003) 1.69
Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation (2004) 1.69
Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis (2005) 1.66
Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann N Y Acad Sci (2006) 1.65
Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol (1997) 1.65
Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev (2003) 1.62
Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. Arterioscler Thromb Vasc Biol (2002) 1.58
IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J Interferon Cytokine Res (2002) 1.58
T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation (2001) 1.57
Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation (2002) 1.56
Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res (2005) 1.49
Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation (1998) 1.40
Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions. Arterioscler Thromb Vasc Biol (2006) 1.39
Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol (2004) 1.37
Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents (1998) 1.37
Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J Lipid Res (1998) 1.35
Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis (2006) 1.34
Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem (1996) 1.31
Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis (2006) 1.31
Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin. Mol Nutr Food Res (2005) 1.30
Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.28
Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2004) 1.28
Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem (2002) 1.28
Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest (1994) 1.27
Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci U S A (2002) 1.26
Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2004) 1.25
Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but does not reduce the size of advanced lesions in apolipoprotein E-deficient mice. Circulation (1999) 1.22
Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice. Circulation (2007) 1.18
Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis (2001) 1.17
Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation (2003) 1.17
Interferon-gamma and atherosclerosis: pro- or anti-atherogenic? Cardiovasc Res (2005) 1.17
Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. Gene Ther (2004) 1.15
Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL. Involvement of nuclear factor-kappa B. Arterioscler Thromb Vasc Biol (1995) 1.14
GM-CSF deficiency reduces macrophage PPAR-gamma expression and aggravates atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (2006) 1.10
Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis (2005) 1.10
Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am J Pathol (2007) 1.09
Macrophage phenotype in mice deficient in both macrophage-colony-stimulating factor (op) and apolipoprotein E. Arterioscler Thromb Vasc Biol (1998) 1.07
Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation (2005) 1.06
Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis (2005) 1.01
The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism. J Atheroscler Thromb (2006) 1.01
Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem (2000) 1.00
IL-6 and the acute phase response in murine atherosclerosis. Atherosclerosis (2004) 1.00
Regulatory T cell responses: potential role in the control of atherosclerosis. Curr Opin Lipidol (2005) 1.00
Lesion progression and plaque composition are not altered in older apoE-/- mice lacking tumor necrosis factor-alpha receptor p55. Atherosclerosis (2004) 0.97
Requisite role for interleukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or Mycobacterium tuberculosis. Circ Res (2000) 0.97
Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol (2004) 0.96
Atherogenic effect of interleukin-2 and antiatherogenic effect of interleukin-2 antibody in apo-E-deficient mice. Angiology (2004) 0.94
Actions and therapeutic potential of G-CSF and GM-CSF in cardiovascular disease. J Mol Cell Cardiol (2006) 0.94
Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. Cardiovasc Res (2005) 0.93
Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis (2004) 0.93
Tumor necrosis factor alpha plays a role in the acceleration of atherosclerosis by Chlamydia pneumoniae in mice. Infect Immun (2005) 0.91
Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis (2004) 0.91
Receptor binding and cellular uptake studies of macrophage migration inhibitory factor (MIF): use of biologically active labeled MIF derivatives. J Interferon Cytokine Res (2002) 0.89
Beyond cholesterol--inflammatory cytokines, the key mediators in atherosclerosis. Clin Chem Lab Med (2004) 0.87
Interleukin (IL)-4 deficiency does not influence fatty streak formation in C57BL/6 mice. Atherosclerosis (2000) 0.85
Postnatal blocking of interferon-gamma function prevented atherosclerotic plaque formation in apolipoprotein E-knockout mice. Hypertens Res (2007) 0.83
Thalidomide inhibits early atherogenesis in apoE-deficient mice. APMIS Suppl (2003) 0.82
MRI follow-up of TNF-dependent differential progression of atherosclerotic wall-thickening in mouse aortic arch from early to advanced stages. Atherosclerosis (2007) 0.80
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 5.28
Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol (2007) 3.36
Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol (2006) 2.70
Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol (2007) 1.80
Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance. PLoS One (2010) 1.64
Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood (2002) 1.60
Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem (2004) 1.55
MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res (2009) 1.49
Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation (2003) 1.27
An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach. Am J Clin Nutr (2010) 1.27
LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms. J Lipid Res (2008) 1.26
Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis (2011) 1.25
Functional characterization of the Plasmodium falciparum and P. berghei homologues of macrophage migration inhibitory factor. Infect Immun (2006) 1.23
Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol (2004) 1.22
Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab (2004) 1.17
cAMP-dependent signaling regulates the adipogenic effect of n-6 polyunsaturated fatty acids. J Biol Chem (2007) 1.11
A combined transcriptomics and lipidomics analysis of subcutaneous, epididymal and mesenteric adipose tissue reveals marked functional differences. PLoS One (2010) 1.09
Transgenic flavonoid tomato intake reduces C-reactive protein in human C-reactive protein transgenic mice more than wild-type tomato. J Nutr (2006) 1.08
Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int (2003) 1.08
Quantitative profiling of bile acids in biofluids and tissues based on accurate mass high resolution LC-FT-MS: compound class targeting in a metabolomics workflow. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.06
Diet-induced obesity increases NF-kappaB signaling in reporter mice. Genes Nutr (2009) 0.98
The NuGO proof of principle study package: a collaborative research effort of the European Nutrigenomics Organisation. Genes Nutr (2008) 0.96
A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS One (2013) 0.96
Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering. Kidney Int (2002) 0.95
Chronic TNF-α neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndrome. Mol Med (2010) 0.95
Differential effects of drug interventions and dietary lifestyle in developing type 2 diabetes and complications: a systems biology analysis in LDLr-/- mice. PLoS One (2013) 0.92
Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. Arterioscler Thromb Vasc Biol (2006) 0.92
Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. J Hypertens (2007) 0.90
Exploring pathway interactions in insulin resistant mouse liver. BMC Syst Biol (2011) 0.89
Semi-automated non-target processing in GC × GC-MS metabolomics analysis: applicability for biomedical studies. Metabolomics (2010) 0.88
Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms. Antioxid Redox Signal (2005) 0.87
Coordinated and interactive expression of genes of lipid metabolism and inflammation in adipose tissue and liver during metabolic overload. PLoS One (2013) 0.86
Anti-inflammatory salicylate beneficially modulates pre-existing atherosclerosis through quenching of NF-κB activity and lowering of cholesterol. Atherosclerosis (2010) 0.85
Improving the analysis of designed studies by combining statistical modelling with study design information. BMC Bioinformatics (2009) 0.85
Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice. Atherosclerosis (2009) 0.84
A dietary mixture containing fish oil, resveratrol, lycopene, catechins, and vitamins E and C reduces atherosclerosis in transgenic mice. J Nutr (2011) 0.83
Arachidonic acid/docosahexaenoic acid-supplemented diet in early life reduces body weight gain, plasma lipids, and adiposity in later life in ApoE*3Leiden mice. Mol Nutr Food Res (2012) 0.83
Beneficial effects of alternate dietary regimen on liver inflammation, atherosclerosis and renal activation. PLoS One (2011) 0.82
Ghrelin and the hyposomatotropism of obesity. Obes Res (2002) 0.82
Bioinformatics for the NuGO proof of principle study: analysis of gene expression in muscle of ApoE3*Leiden mice on a high-fat diet using PathVisio. Genes Nutr (2008) 0.82
Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy. Pharmacogenet Genomics (2012) 0.81
Preoperative predictors of postsurgical adhesion formation and the Prevention of Adhesions with Plasminogen Activator (PAPA-study): results of a clinical pilot study. Fertil Steril (2008) 0.81
A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis. BMC Syst Biol (2011) 0.81
A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone. BMC Med Genomics (2014) 0.79
Identification of prognostic and diagnostic biomarkers of glucose intolerance in ApoE3Leiden mice. Physiol Genomics (2012) 0.79
Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice. Atherosclerosis (2009) 0.78
A role for the fibrinolytic system in postsurgical adhesion formation. Fertil Steril (2005) 0.78
Beneficial effects of an alternating high- fat dietary regimen on systemic insulin resistance, hepatic and renal inflammation and renal function. PLoS One (2012) 0.78
Effects of chocolate supplementation on metabolic and cardiovascular parameters in ApoE3L mice fed a high-cholesterol atherogenic diet. Mol Nutr Food Res (2013) 0.78